BeiGene (BGNE)
(Delayed Data from NSDQ)
$201.99 USD
+3.40 (1.71%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $202.05 +0.06 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BGNE 201.99 +3.40(1.71%)
Will BGNE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BGNE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BGNE
Wall Street Analysts See a 27.84% Upside in BeiGene (BGNE): Can the Stock Really Move This High?
BeiGene, Ltd. (BGNE) Just Flashed Golden Cross Signal: Do You Buy?
BGNE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 40.85% Upside in BeiGene (BGNE): Can the Stock Really Move This High?
Argenx (ARGX) Surges 11.7%: Is This an Indication of Further Gains?
Travere (TVTX) Stock Jumps 5.2%: Will It Continue to Soar?
Other News for BGNE
What Analysts Are Saying About BeiGene Stock
BeiGene initiated with bullish view at JMP Securities, here's why
BeiGene initiated at outperform at JMP Securities on strength of Brukinsa
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
Reni Benjamin Endorses BeiGene with a Buy Rating Amidst Strong Financial Outlook and Market Penetration